SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is a central topic of discussion, driven by its presentation at the J.P. Morgan Healthcare Conference, alongside recent announcements including the appointment of a Chief Commercial Officer and completion of enrollment for its VK2735 maintenance dosing study. The community is sharply divided: bulls emphasize the drug's "best-in-class" potential, robust clinical data, and strategic leadership moves positioning the company for significant partnerships in the rapidly expanding GLP-1 obesity market. Conversely, skeptics point to persistent stock underperformance, past insider selling, and the formidable competition, questioning the company's ability to capitalize on its assets and anticipating a "sell the news" reaction from the conference.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid discussions surrounding potential new tariffs on countries trading with Iran and a reported DOJ probe into Fed Chair Powell, sparking debate on market stability and the independence of the central bank. Despite these headlines, a strong bullish sentiment prevails among many, emphasizing buying opportunities during dips and highlighting the market's resilience. The community is actively discussing whether the market can sustain its upward momentum given these geopolitical and regulatory concerns, often with frustration from those anticipating a significant pullback.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is trending due to strategic announcements around its ambitious "Meta Compute" AI infrastructure buildout, which includes securing multi-gigawatt nuclear energy agreements to power future data centers. This aggressive AI push, alongside reported layoffs in the Reality Labs division, is sparking mixed community reactions regarding the scale of investment versus potential returns. Investors are keenly observing these developments as Meta intensifies its position in the global AI race, with many awaiting further clarity on the long-term vision.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is experiencing strong upward momentum, driven by growing optimism for its Artificial Intelligence and Cloud divisions. The community is buzzing about this breakout, fueled by reports of resumed high-performance AI chip shipments to China and a broader positive sentiment shift toward the Chinese tech sector. Many anticipate a significant re-rating as investors eye reallocation into these names.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics is trending due to the FDA's decision to waive the Advisory Committee meeting for its FILSPARI supplemental New Drug Application in Focal Segmental Glomerulosclerosis (FSGS). The community interprets this as a significant de-risking signal, fostering optimism for a potential approval given the high unmet need for FSGS treatments. With FILSPARI already approved for IgA nephropathy, the focus is on this crucial label expansion and its implications for the company's market position.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending due to a new partnership and pre-production order with a major U.S. defense contractor, fueling anticipation for a substantial contract to supply advanced computing systems for Army combat vehicles. The community is buzzing with discussion about the immense potential in edge AI and defense, viewing OSS as significantly undervalued with a tight float and strong growth prospects in AI infrastructure, especially after a strategic asset sale to sharpen its focus.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending due to significant community excitement surrounding its multi-year AI partnership with Apple, which will integrate Google's Gemini into Siri and Apple's next-generation Foundation Models. This development is widely seen as a major win in the AI race, solidifying Gemini's competitive position and extending its reach across billions of devices. Conversations highlight Google's expanding AI leadership, including new partnerships in agentic commerce and its implications for the company's market valuation.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending due to anticipation surrounding its upcoming JPM Healthcare Conference presentation and updated investor materials, which highlight strategic directions including a new 12% market share in Japan. Community discussion is heavily focused on the company's substantial short interest, sparking speculation of a potential short squeeze, while also voicing strong calls for management to secure significant partnerships or a buyout to unlock the value of its vaccine technology.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

Taiwan Semiconductor is a hot topic as a potential US-Taiwan trade deal emerges, poised to secure significant new fab investments in Arizona and bolster US chip production. The community highlights the company's critical role in meeting insatiable global AI chip demand, a key driver underpinning its market leadership despite persistent geopolitical tensions.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is a hot topic after successfully closing a $1 billion offering to a single institutional investor, a move largely interpreted by the community as a strong bullish signal. This substantial capital, alongside a raised price target from Stifel and the Department of Homeland Security's new focus on drone and counter-drone technologies, positions Ondas for significant growth in critical defense and security markets. Community discussions are highly anticipatory, expecting further strategic acquisitions and major contract announcements, especially with an investor day on the horizon.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;</li><li>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment.</li><li>Test volumes climbed to 18,000 in Q4 and 62,600 for the year.</li></ul>Biodesix Inc. (BDSX) stock surged over 23% in Monday’s premarket after the Colorado-based diagnostics firm provided a strong outlook for the fourth quarter (Q4) and fiscal year 2025.&nbsp;The company expects Q4 revenue of $28.8 million, a 41% year-over-year (YoY) increase, while full-year revenue is estimated at $88.5 million, up 24% YoY. The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Growth Driven By Lung Diagnostics</h2>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment, which is estimated to have generated $25.2 million in Q4 and $79.2 million for the full year. The results reflect a 47% and 22% YoY increase, respectively.&nbsp;Test volumes climbed to 18,000 in Q4 and 62,600 for the year, rising 23% and 15% from the previous year. The increase was driven by higher test volumes, stronger revenue per test, and about $1 million in collections from older claims.&nbsp;<blockquote>“Biodesix finished 2025 with a strong fourth quarter, delivering full year estimated revenue of $88.5 million, exceeding the top end of our increased guidance of $84-$86 million.”-Scott Hutton, CEO, Biodesix</blockquote>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/BDSX">Biodesix stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_12_084117_png_27b632f1b5.webp" alt="BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits" width="931" height="98"><figcaption>BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Development Services&nbsp;</h2>The company’s development services segment contributed an estimated $3.6 million in Q4 and $9.3 million for 2025, representing growth of 13% and 41% over the prior year, respectively.&nbsp;“Based on our strong revenue flow-through and operating leverage, we are affirming our expectation of positive Adjusted EBITDA in the fourth quarter,” added Hutton.&nbsp;Biodesix said it ended 2025 with $19.0 million in cash and cash equivalents, a 14% increase over the previous quarter.&nbsp;BDSX stock declined by over 77% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-captures-20-of-global-smartphone-market/cmU96DMR4E4">Apple Captures 20% Of Global Smartphone Market, But Rising Memory Costs Cast Shadow On 2026 Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Biodesix logo is seen displayed on a smartphone screen.

BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge? 

The company expects Q4 revenue of $28.8 million, a 41% year-over-year increase, while full-year revenue is estimated at $88.5 million, up 24% year-over-year.

This Diagnostics Stock Is Surging 23% Pre-Market Today – Here’s Why 

Equity

SOLV Acquires Acera Surgical to Expand Advanced Wound Care Portfolio

Solventum buys Acera Surgical for $725M upfront to enter tissue matrices, expanding MedSurg and wound care.

Biodesix, Inc. (NASDAQ:BDSX) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are covering the stock, MarketBeat.com reports. One analyst...

Cencora to Acquire OneOncology to Expand Community Oncology Solutions

COR's $3.6 billion move to take control of OneOncology boosts its pharma-centric strategy and lifts its long-term growth outlook despite a short-term dip.

Wall Street Analysts Believe Biodesix (BDSX) Could Rally 325.67%: Here's is How to Trade

The mean of analysts' price targets for Biodesix (BDSX) points to a 325.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Biodesix, Inc. (NASDAQ:BDSX) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six ratings firms that are currently covering the stock, Marketbeat.com...

Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates

Biodesix (BDSX) delivered earnings and revenue surprises of +27.50% and +2.68%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Teladoc (TDOC) Reports Q3 Loss, Beats Revenue Estimates

Teladoc (TDOC) delivered earnings and revenue surprises of +19.23% and +0.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Revvity (RVTY) Surpasses Q3 Earnings Estimates

Revvity (RVTY) delivered earnings and revenue surprises of +3.51% and -0.15%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates

Biodesix (BDSX) delivered earnings and revenue surprises of -14.29% and +7.34%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Stocktwits

Stocktwits Polls

The company announced preliminary Q4 revenue soared 41% and full-year revenue rose 24%, exceeding guidance and sparking significant interest.

A reported low float around 4.39 million shares, coupled with high price targets from analysts, fuels intense speculation for a short squeeze.

Shares experienced rapid price fluctuations and multiple trading halts, fueled by massive volume and speculation.

Traders are debating the significance of around $19 million in cash reserves, with some warning of potential dilution despite recent positive financial updates.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.90	--	--	N/A
Q3 '25	-$1.49	-$1.16	22.15%	BEAT
Q2 '25	-$0.07	-$1.60	-2216.59%	MISSED
Q1 '25	-$0.07	-$0.08	-14.64%	MISSED
Q4 '24	-$0.07	-$0.06	10.74%	BEAT

BDSX
Biodesix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest BDSX News

BDSXBiodesix Inc